key: cord-0922483-6b0k5bq3
authors: Pilarowski, Genay; Lebel, Paul; Sunshine, Sara; Liu, Jamin; Crawford, Emily; Marquez, Carina; Rubio, Luis; Chamie, Gabriel; Martinez, Jackie; Peng, James; Black, Douglas; Wu, Wesley; Pak, John; Laurie, Matthew T; Jones, Diane; Miller, Steve; Jacobo, Jon; Rojas, Susana; Rojas, Susy; Nakamura, Robert; Tulier-Laiwa, Valerie; Petersen, Maya; Havlir, Diane V; DeRisi, Joseph
title: Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco
date: 2021-01-04
journal: J Infect Dis
DOI: 10.1093/infdis/jiaa802
sha: 06349762add27d62601fe4f9e7fb58bf9bd4bab4
doc_id: 922483
cord_uid: 6b0k5bq3

We evaluated the performance of the Abbott BinaxNOW (TM) Covid-19 rapid antigen test (Binax-CoV2) to detect virus among persons, regardless of symptoms, at a public plaza site of ongoing community transmission. Titration with cultured SARS-CoV-2 yielded a human observable threshold between 1.6x10 (4)-4.3x10 (4) viral RNA copies (cycle threshold (Ct) of 30.3-28.8). Among 878 subjects tested, 3% (26/878) were positive by RT-PCR, of which 15/26 had Ct<30, indicating high viral load. 40% (6/15) of Ct<30 were asymptomatic. Using this Ct<30 threshold for Binax-CoV2 evaluation, the sensitivity of Binax-CoV2 was 93.3% (14/15), 95% CI: 68.1-99.8%, and the specificity was 99.9% (855/856), 95% CI: 99.4-99.9%.

The global pandemic of SARS-CoV-2 infection has spread at an unprecedented pace [1] fueled by efficient transmission of infection by the respiratory route, including by asymptomatic and pre-symptomatic persons. Instances of successful control utilize masking, social distancing, and aggressive testing, tracing, and quarantine [2] .

To date, the cornerstone of testing has been RT-PCR examination of respiratory secretions which has excellent sensitivity and specificity but is expensive and requires sophisticated equipment and highly trained personnel [3] . In practice, these features have often generated testing delays compromising their utility [4] . As a result, there is interest in rapid and economical assays that circumvent these limitations [5] . However, methods that do not include an amplification step are inherently less sensitive; their proper deployment will therefore require a rigorous evaluation of performance characteristics in different epidemiologic settings.

Lateral flow antigen detection diagnostics have been deployed for a variety of infectious diseases including malaria, RSV, and influenza. The Abbott BinaxNOW TM COVID-19 Ag Card (hereafter referred to as Binax-CoV2) is one such assay that detects viral nucleocapsid (N) protein directly from nasal swabs. The test requires no instrumentation; results are scored visually and returned within 15 minutes. In August 2020, the FDA issued an emergency use authorization (EUA) for the diagnosis of SARS-CoV-2 infection in symptomatic patients within 7 days of symptom onset [6] . The US Department of Health and Human Services has distributed 150 million test kits. Given the value of a rapid assessment A c c e p t e d M a n u s c r i p t of infectiousness, there is anticipated use in a broad range of subjects, including those who are asymptomatic.

Here we present a systematic examination of the performance characteristics of the Binax-CoV2 test in a community screening setting where testing was offered for symptomatic and asymptomatic subjects.

Over 3 days in September 2020, we offered testing in the Mission District, a Latinxpredominant neighborhood, known from prior surveys to have an elevated prevalence of SARS-CoV-2 infection [7, 8] . Walk-up, free testing was conducted at a plaza located at an intersection of the Bay Area-wide subway system (BART) and the San Francisco city bus/streetcar system (MUNI). On the day of test, participants self-reported symptoms and date of onset, demographics, and contact information, as required by state and federal reporting guidelines. A laboratory technician performed sequential anterior swab (both nares) for the Binax-CoV2 assay followed by a second swab (both nares) for RT-PCR. RT-PCR detection of SARS-CoV-2 was performed at the CLIA-certified lab operated by UCSF and the Chan Zuckerberg Biohub as described [9, 10] .

The Binax-CoV2 assay was performed by technicians on site as described by the manufacturer using the supplied swabs. Each assay was read by two independent observers, and a site supervisor served as a -tie-breaker‖. Beginning on day 2 of the study, each Binax-CoV2 assay card was scanned onsite using a color document scanner (CanoScan LIDE 400, Canon). Sample bands were retrospectively quantified from image data. Sample and background regions were localized by offset from the control band and relative mean pixel intensity decreases were calculated from blue and green channels averaged with respect to background.

SARS-CoV-2 from a UCSF clinical specimen was isolated, propagated and plaqued on Huh7.5.1 cells overexpressing ACE2 and TMPRSS2 [11] . Viral titers were determined using standard plaque assays [12] . For titration experiments, SARS-CoV-2 was diluted in Dulbecco's phosphate-buffered saline (DPBS) and 40 microliters of each dilution was absorbed onto the supplied swabs. Images of Binax-CoV2 cards were taken on an Apple iPhone6. All experiments using cultured SARS-CoV-2 were conducted in a biosafety level 3

A c c e p t e d M a n u s c r i p t N protein titration assay SARS-CoV-2 N protein (1-419) was expressed in BL21(DE3) E.coli and purified by Ni-NTA chromatography, incorporating a 1M NaCl, 50 mM imidazole wash to remove bound RNA.

Six concentrations of N protein were tested on ten lots of Binax-CoV2 kits. 40ul of N protein was absorbed onto the provided swab.

The UCSF Committee on Human Research determined that the study met criteria for public health surveillance. All participants provided informed consent for dual testing.

To explore the relationship of RT-PCR cycle threshold (Ct), viral load, and the corresponding visual Binax-CoV2 result, a dilution series of lab-cultured SARS-CoV-2 with known titers was assayed both by RT-PCR and by Binax-CoV2 (Figure 1) . For this stock of virus, the threshold for detectability by human eye on the Binax-CoV2 assay was between 1.6-4. A c c e p t e d M a n u s c r i p t

Of the 878 subjects tested, 54% were male, 77% were 18 to 50 years of age, 81% selfidentified as Latinx, and 84% reported no symptoms in the 14 days before testing. Twentysix persons (3%) were RT-PCR(+); of these, 15/26 (58%) had a Ct<30 and 6/15 (40%) were asymptomatic. Among asymptomatic individuals with Ct<30, 4/6 developed symptoms within 2 days after testing. Of the 11 persons RT-PCR-positive with Ct>30, 4 reported symptom onset > 7 days before testing, 1 reported symptom onset 3 days prior to testing, and the remainder reported no symptoms. (Figure 2b) . In each case, the corresponding image is shown in order to demonstrate the correspondence between RT-PCR and the visual result (Figure 2c) .

A c c e p t e d M a n u s c r i p t

RT-PCR is considered a gold standard [3] and, in this assay, has a limit of detection of 100 viral RNA copies per mL. Direct antigen assays are inherently not as sensitive as RT-PCR.

In the context of community based testing, we defined a threshold for high virus levels corresponding to the range of highest probability of transmissibility: a cycle threshold of 30, which corresponds to a viral RNA copy number of approximately 1.9x10 4 in this assay [10, 13] . Using this Ct<30 case definition and 95% confidence interval (CI), the sensitivity of 99.6%-100%). Given that the Binax-CoV2 assay detects infected individuals with high levels of virus (>10 4 ), the sensitivity of the assay in the absence of a threshold will largely depend on the viral kinetics within the testing population. Sensitivity/specificity calculations were completed using retroactive Binax-CoV2 scores from images covering all three study days with the final scoring criteria.

We quantified lot-to-lot variability in 10 different lots of Binax-CoV2 card tests using a dilution series of N protein. (Supplementary Figure 1) . At protein concentrations of 17.2ng/ml and greater, sample band was detected in all lots, and thus would not affect the outcome of this binary assay (Supplementary Figure 1A) .

A c c e p t e d M a n u s c r i p t

These data describe the performance characteristics of the Binax-CoV2 antigen detection kit in the context of community testing including asymptomatic subjects. These results indicate a clear relationship between relative viral load and test positivity and provide a practical, real-world criterion to assist calling results in this setting. We found that small training modifications reduced the presence of false-positives, a legitimate concern for the roll-out of these tests.

The currently approved EUA for the Binax-CoV2 assay specifies use only in symptomatic individuals. The results presented here suggest that the Binax-CoV2 test should not be limited to symptomatic testing alone. Many asymptomatic individuals have high viral loads (corresponding to low Ct's) and, therefore, have a high probability of being infectious and transmitting the virus, a feature and likely driver of the pandemic that we and others have observed previously [7, 14] . Limiting use of Binax-CoV2 to symptomatic individuals would have missed nearly half of the SARS-CoV-2 infections in this study.

Furthermore, the impact of testing on forward transmission is hampered by long wait times.

We reported previously that in the community setting, by the time a person is tested, counseled and situated under isolation conditions, the effective isolation period is often nearly over [8]. This is particularly true for many communities of color, where reported delays in accessing tests and results are even longer [4, 15] . Rapid tests could reduce these delays and maximize time of effective isolation. Limitations of our study include its cross-sectional design and overall small number of RT-PCR positive cases. Additional field performance of this assay is needed and will help inform optimal use strategies. We recommend evaluating A c c e p t e d M a n u s c r i p t the Binax-CoV2 assay side by side with RT-PCR in each context it will be used prior to use of Binax-CoV2 without the use of RT-PCR.

During the early stages of infection, viral load may be too low to detect by direct antigen assays such as Binax-CoV2. This inherent lower sensitivity may be offset by faster turnaround and higher frequency of testing, with overall lower cost, relative to RT-PCR methods.

That said, for persons who present with a high index of suspicion of COVID-19 and a negative Binax-CoV2 result, the test should be complemented with RT-PCR or a repeat Binax-CoV2 test at a later time to make sure case not missed.

In summary, under field conditions with supplementary technician training, the Binax-CoV2 assay accurately detected SARS-CoV-2 infection with high viral loads in both asymptomatic and symptomatic individuals. The Binax-CoV2 test could be a valuable asset in an arsenal of testing tools for the mitigation of SARS-CoV-2 spread, as rapid identification of highly infectious individuals is critical. M a n u s c r i p t

COVID-19 Map -Johns Hopkins Coronavirus Resource Center

Successful Elimination of Covid-19 Transmission in New Zealand

Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection

The State of the Nation: A 50-State Covid-19

Covid-19 Test Result Times. Available from: www.covidstates.org

Rethinking Covid-19 Test Sensitivity -A Strategy for Containment

Abbott BinaxNOW COVID-19 Ag Package Insert, version 1.6. 2020

Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco

Rapid deployment of SARS-CoV-2 testing: The CLIAHUB

Identification of a polymorphism in the N gene of SARS-CoV-2 that adversely impacts detection by RT-PCR

Functional genomic screens identify human host factors for SARS-CoV-2 and common cold coronaviruses. bioRxiv Prepr Serv Biol. Cold Spring Harbor Laboratory Preprints

Rapid quantification and neutralization assays for novel coronavirus SARS-CoV-2 using

Avicel R RC-591 semi-solid overlay

Virological assessment of hospitalized patients with COVID-2019

Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review

Assessment of Disparities in COVID-19 Testing and Infection Across Language Groups in

The authors report no commercial or other association that might pose a conflict of interest.The content of this manuscript represents original work and has not been submitted or accepted for publication or presented at professional meetings.This study was supported by UCSF, the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative, the San Francisco Latino Task Force, and a private donor. LR was funded by T32 AI060530, and SS was funded by NIAID (F31AI150007).To whom correspondence should be addressed: 

This study was supported by UCSF, the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative, the San Francisco Latino Task Force, and a private donor. LR was funded by T32 AI060530, and SS was funded by NIAID (F31AI150007).

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t